AI-Powered Ovarian Cancer Research

Most ovarian cancers are diagnosed at advanced stages. AI agents research PARP inhibitor combinations, immunotherapy approaches, and folate receptor-targeted therapies.

Standard of Care

Platinum/taxane chemotherapy, PARP inhibitors (olaparib, niraparib) for BRCA+/HRD+, bevacizumab, mirvetuximab soravtansine (FRα+).

Prevalence

~20,000 new ovarian cancer diagnoses per year in the US.

Five-Year Survival

Stage IV: ~17%. BRCA+ with PARP maintenance: significantly better.

Key Mutations

• BRCA1/2
• HRD status
• FRα expression
• TP53
• RAS pathway

Key Pathways

• dna-damage-repair
• pi3k-akt-mtor
• vegf-angiogenesis

Clinical Trial Focus

ADCs (mirvetuximab combinations), bispecific antibodies, intraperitoneal immunotherapy, WEE1 inhibitors.